Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals Inc (HEPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Hepion Pharmaceuticals Inc 399 THORNALL STREET FIRST FLOOR EDISON NJ 08837 USA

www.hepionpharma.com Employees: 22 P: 732-902-4000 F: 732-902-4100

Description:

Hepion Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis and chronic hepatitis virus infection. The Company's lead drug candidate CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Hepion Pharmaceuticals Inc., formerly known as ContraVir Pharmaceuticals Inc., is based in Edison, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 3,410
Enterprise Value, $K -9,290
Shares Outstanding, K 6,958
Annual Sales, $ 0 K
Annual Net Income, $ -48,930 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,870 K
EBIT, $ -25,360 K
EBITDA, $ -22,100 K
60-Month Beta 1.63
% of Insider Shareholders 1.95%
% of Institutional Shareholders 17.24%
Float, K 6,823
% Float 98.05%
Short Volume Ratio 0.37

Growth:

1-Year Return -83.28%
3-Year Return -98.13%
5-Year Return -99.55%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 55.68%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.72 on 11/14/24
Next Earnings Date 11/18/24
Earnings Per Share ttm -4.38
EPS Growth vs. Prev Qtr -5.88%
EPS Growth vs. Prev Year 73.72%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 05/11/23

HEPA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -812.56%
Return-on-Assets % -207.31%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.07
Interest Coverage -4,933.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar